Intravenous zanamivir has been used to treat patients with severe influenza. Because the majority of cases (including immunocompromised patients) require the drug for an extended period of treatment, there is a higher risk that the virus will develop resistance. Therefore, knowing the possible amino acid substitutions that may arise in recently circulating influenza strains under prolonged zanamivir exposure and their impact on antiviral susceptibility is important.
Methods
Influenza A(H1N1)pdm09, A(H3N2) and B virus were serially passaged under increasing zanamivir pressure in vitro. Neuraminidase (NA) mutations that arose were introduced into recombinant viruses and the susceptibility to oseltamivir, zanamivir, peramivir and laninamivir was determined. The replication fitness of the recombinant variants was assessed in the ferret.
Results
NA mutations E119D (N1 numbering) and E117D (B numbering) were detected in A(H1N1)pdm09 and B (Victoria-lineage) viruses respectively and were associated with reduced susceptibility to all four NA inhibitors. No NA mutations were detected in the A(H3N2) or B (Yamagata-lineage) viruses. In ferrets, the A(H1N1) pdm09 E119D variant caused a lower degree of morbidity and the mutation was found to be unstable with E119 reverted virus detected 4 days post-infection of ferrets with the variant E119D virus. In contrast, the influenza B E117D variant was genetically stable in ferrets, caused a noticeable level of morbidity but had a significant reduction in replication fitness compared to wild-type virus.
Conclusions
The NA mutations E119D in influenza A(H1N1)pdm09 and E117D in influenza B viruses that arose under zanamivir pressure conferred resistance to multiple NA inhibitors but had compromised viral replication in ferrets compared to wild-type virus without antiviral drug pressure.
References
1.
LowenA.C., MubarekaS., TumpeyT.M., Garcia-SastreA., PaleseP.The guinea pig as a transmission model for human influenza viruses.Proc Natl Acad Sci U S A2006; 103: 9988–9992.
2.
China's SFDA ready to fast-track approvals of peramivir, a flu treatment.ChinaBioToday. (Updated 8 April 2013. Accessed 13 April 2014.) Available from http://www.chinabiotoday.com/articles/20130408_1.
IkematsuH., KawaiN.Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.Expert Rev Anti Infect Ther2011; 9: 851–857.
5.
WijayaL., ChuaY.Y., CuiL., ChanK., TanB.H.Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus.Singapore Med J2011; 52: 481–485.
6.
MartyF.M., ManC.Y., van der HorstC.Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, Phase II study.J Infect Dis2014; 209: 542–550.
7.
Chan-TackK.M., KimC., MorufA., BirnkrantD.B.Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011–2014).Antivir Ther2015; 20: 561–564.
8.
KiddI.M., DownJ., NastouliE.H1N1 pneumonitis treated with intravenous zanamivir.Lancet2009; 374: 1036.
9.
GlaxoSmithKline. A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza. (Updated 18 July 2016. Accessed 5 December 2016.) Available from http://www.gsk-clinicalstudyregister.com/study/114373#ps.
10.
Chan-TackK.M., GaoA., HimayaA.C.Clinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States.J Infect Dis2013; 207: 196–198.
11.
L'HuillierA.G., AbedY., PettyT.J.E119D neuraminidase mutation conferring pan-resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient.J Infect Dis2015; 212: 1726–1734.
12.
AbedY., BouhyX., L'HuillierA.G.The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.Antiviral Res2016; 132: 6–12.
13.
BaekY.H., SongM.S., LeeE.Y.Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.J Virol2015; 89: 287–299.
14.
BurnhamA.J., ArmstrongJ., LowenA.C., WebsterR.G., GovorkovaE.A.Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.J Virol2015; 89: 4575–4587.
15.
BurnhamA.J., BaranovichT., MaratheB.M., ArmstrongJ., WebsterR.G., GovorkovaE.A.Fitness costs for influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.Antimicrob Agents Chemother2014; 58: 2718–2730.
16.
PascuaP.N., MaratheB.M., BurnhamA.J.Competitive fitness of influenza B viruses possessing E119A and H274Y neuraminidase inhibitor resistance-associated substitutions in ferrets.PLoS One2016; 11: e0159847.
17.
GubarevaL.V., BethellR., HartG.J., MurtiK.G., PennC.R., WebsterR.G.Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.J Virol1996; 70: 1818–1827.
18.
McKimm-BreschkinJ.L., SahasrabudheA., BlickT.J.Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.J Virol1998; 72: 2456–2462.
19.
TaiC.Y., EscarpeP.A., SidwellR.W.Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.Antimicrob Agents Chemother1998; 42: 3234–3241.
20.
BarnettJ.M., CadmanA., BurrellF.M.In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.Virology1999; 265: 286–295.
21.
ChaudhryA., BastienN., LiY.Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014–2015 influenza season in Alberta, Canada.Influenza Other Respir Viruses2016; 10: 532–535.
22.
TamuraD., DeBiasiR.L., Okomo-AdhiamboM.Emergence of multidrug-resistant influenza A(H1N1) pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir.J Infect Dis2015; 212: 1209–1213.
HurtA.C., Okomo-AdhiamboM., GubarevaL.V.The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.Methods Mol Biol2012; 865: 115–125.
25.
MaratheB.M., LevequeV., KlumppK., WebsterR.G., GovorkovaE.A.Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate.PLoS One2013; 8: e71401.
26.
HoffmannE., KraussS., PerezD., WebbyR., WebsterR.G.Eight-plasmid system for rapid generation of influenza virus vaccines.Vaccine2002; 20: 3165–3170.
27.
HoffmannE., NeumannG., KawaokaY., HobomG., WebsterR.G.A DNA transfection system for generation of influenza A virus from eight plasmids.Proc Natl Acad Sci U S A2000; 97: 6108–6113.
28.
HoffmannE., MahmoodK., YangC.F., WebsterR.G., GreenbergH.B., KembleG.Rescue of influenza B virus from eight plasmids.Proc Natl Acad Sci U S A2002; 99: 11411–11416.
29.
OhD.Y., BarrI.G., HurtA.C.A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.PLoS One2015; 10: e0118780.
30.
MontoA.S., MaassabH.F.Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test.J Clin Microbiol1981; 13: 54–57.
31.
TakashitaE., MeijerA., LackenbyA.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014.Antiviral Res2015; 117: 27–38.
32.
HurtA.C., BesselaarT.G., DanielsR.S.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015.Antiviral Res2016; 132: 178–185.
33.
MeijerA., Rebelo-de-AndradeH., CorreiaV.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013.Antiviral Res2014; 110: 31–41.
34.
GubarevaL.V., MatrosovichM.N., BrennerM.K., BethellR.C., WebsterR.G.Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.J Infect Dis1998; 178: 1257–1262.
35.
SheuT.G., DeydeV.M., GartenR.J., KlimovA.I., GubarevaL.V.Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.Antiviral Res2010; 85: 354–360.
36.
MishinV.P., HaydenF.G., GubarevaL.V.Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.Antimicrob Agents Chemother2005; 49: 4515–4520.
37.
ButlerJ., HooperK.A., PetrieS.Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.PLoS Pathog2014; 10: e1004065.
38.
PizzornoA., BouhyX., AbedY., BoivinG.Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.J Infect Dis2011; 203: 25–31.
